50 years of history

 

 

With 50 years of experience in the pharmaceutical and medical device fields, Hanmi Science,
Has developed the Ofmom formula, thanks to the close collaboration with scientific organizations worldwide

 

From the collaboration of our R&D with pediatricians and gastroenterologists,
The Ofmom formula was developed, paying attention to safe regulations established by reference markets (Europe, USA and Asia)

2019

LAUNCHED ‘OFMOM SYNTERACT™ BIMBI’ 14 STICK IN ITALIAN MARKET (DEVELOPED AND MANUFACTURED IN ITALY)

 

 

Sponsored SIGENP (Società Italiana di Nutrizione e Gastroenterologia Pediatrica) www.congresso.sigenp.org/2019/home

 

Sponsored Rome congress 2019 ’10th Probiotics, Prebiotics & New Foods’ (www.probiotics-prebiotics-newfood.com)

 

Hanmi, co-promoted an agreement of ‘Diquas’ with Santen Pharmaceutical Co., Ltd.

 

Announced 2018 earnings 880 million of euro in sales, 19% R&D investment against sales

2018

LAUNCHED 'OFMOM PROBIOTICS FORMULA MADE' IN CHINESE MARKET

 

 

Set up a maternal and infant biobank in Rome, cooperating with Catholic University of the Sacred Heart and Agostino Gemelli University Policlinic

 

Established Centre Ofmom and held on the first international symposium on the care of mother and child in Rome

 

Launched Monterizine Chewable Tab for children

 

Received FDA orphan drug designation for HM43239 in treatment of AML

 

Janssen, started phase 2 study on HM12525A, a biologic drug for the treatment of diabetes and obesity developed by Hanmi

 

Received industry first ‘BPW Gold Award’ for promoting gender equality

 

Announced reports 690 million of euro in revenue in 2017.

2017

LAUNCHED ‘ITALIAN PREMIUM LIQUID MILK’ IN ASIAN MARKET (KOREA & CHINA), COLLABORATING WITH GRANAROLO S.P.A.

 

 

Co-researched & developed on the public health between Korea and Italy with Catholic University of the Sacred Heart and Agostino Gemelli University General Hospital

 

Released hypertension-hyperlipidemia three-compound complex Amosartan Q (amlodipine +losartan+rosuvastatin)

 

Released 3-compound hypertension drug ‘Amosartan Plus (losartan/amlodipine/chlortalidon)’

 

Launched the first osteoporosis therapy in the world which combines SERM with Vitamin D

 

Launched ‘Monterizine’, a combination drug for patients with both asthma and allergic rhinitis

 

Launched ‘Besigum’, a treatment for overactive bladder syndrome treatment

 

Hanmi-MSD, signed an agreement to export ‘Rosuzet’ to 23 countries

 

Unveiled new R&D strategy at JP Morgan Healthcare Conference

2016

ESTABLISHED COREE S.R.L. & OFMOM S.R.L. AND CENTRE OFMOM USA

 

 

‘Mami Ai’, awarded as the ‘2016 annual trusted intestinal health brand of Chinese mothers’

 

Presented at the Europe symposium of cancer, the results of the preclinical studies of ‘HM95573 (pan-RAF inhibitor)’

 

Signed an exclusive license agreement with Genentech for a new oral RAF inhibitor

2015

ESTABLISHED A POSTNATAL CARE CENTER 'CENTRE OFMOM' WHERE PROVIDES PREMIUM SERVICES TO RECOVER MOTHER'S HEALTH AFTER THE CHILDBIRTH

 

 

3rd-generation EGFR TKI, HM61713(Olmutinib), received FDA Breakthrough Therapy Designation in lung cancer

 

Launched oral wound rinse ‘MuGard’ for cancer patients

 

Hanmi and Sanofi, announced License Agreement to develop Portfolio of Long-Acting Diabetes Treatments

 

Launched new dual-action hyperlipidemia drug ‘Rosuzet’

 

Licensed out ‘Poziotinib’ (targeted anticancer agent) to Spectrum Pharma in US

 

Licensed out immunological therapy ‘HM71224’ to Eli lilly (Deal size : 593 million of euro)

17 million of euro invested in strategic with Allegro Ophthalmics (ophthalmic Bioventure)

2014

Established the first company 'Ofmom' in Hongkong

 

 

‘Mami Ai’, Probiotics for kids in Beijing Hanmi, is registered as China Famous Trade Mark

 

Received ‘fair trade corporation’ award by Fair Trade Commission

 

Launched ‘Fluterol’, DPI type asthma treatment drug

2013

Launched HIMD for the treatment of gastroesophageal reflux disease, ‘Esomezol’ in the United States

 

 

Launched ‘Robelito’, the first ARB-Statin combination drug in Korea, collaborating with Sanofi

 

Launched ‘Naxozol’, an NSAIDs-PPI combination drug

 

Exported Hanmi IMD (Esomezol, Amosartan, Pidogul) to seven countries of South-Est Asia through DKSH

 

Hanmi antibiotic powder injection, achieved the first EU GMP acquisition in the nation

 

Licensed ‘Amosartan’ in the three states of CIS and Uzbek

 

Launched ‘Fenocid’ for the management of cholesterol and triglycerides (fatty acids) in the blood.

2012

Selected as a Pharmaceutical Company of Innovation, by Ministry of Welfare

 

 

Launched ‘Koennasal spray’ (Hyalu acid+Dexpantenol)

 

Collaborated on new drug development with Kainos

 

Received the CE mark for Hyalrheuma from UK SGS

 

LAPS-GCSF, Collaborated with Spectrum (US)

 

The 11th Hanmi literature awards

 

Beijing Hanmi, accredited as ‘R&D Center’ by Beijing Government

2011

Hanmi’s ‘ORASCOVERY’ technology, licensed out to USA

 

 

Published Amosartan clinical study on BMC Research Note

2010

Ranked 1st in R&D investment among Korean pharmaceutical companies

 

 

Initiated the clinical trials of Amosartan in Europe

2009

Co-promoted an agreement with Lundbeck for Ebixa, a treatment for Alzheimer’s disease

 

 

Launched ‘Amosartan’, an antihypertensive combination drug of Amlodipine and Losartan

2008

'Mami Ai', selected Top brand as a medicine for intestinal disorders for children in China

2006

Developed successfully Mexibufen Syrup, using alternative salt

 

 

Published clinical study of Amlodipine

2004

Patent for Amlodipine, a new chemical form of Amlodipine salt

 

 

Developed Successfully Fedipine table, a 24H controlled-release formulation of Nifedipine

2000

Established Hanmi medicare Co.,Ltd.

 

 

Succeeded in the development of the world’s first oral anti-tumor “Paclitaxel”

1999

Made inroads into the European markets through acquisition of Certificates Of Suitability (COS) for the first time in Korea

1997

BROKE 70 MILLION OF EURO BARRIER IN SALES

1996

Established Hanmi Pharmaceutical Co.,Ltd. In China

1992

Launched 'Mami Ai' probiotics for kids

1983

Co-developed an original probiotics medicine studied clinically with Dr. Brochu

 

 

Establishment of Hanmi Fine Chemical Co., an affiliated company of Hanmi Pharmaceutical

1973

Founded Hanmi Pharmaceutical Co.,Ltd. In Korea by Sung-ki Lim

Contact us
Ofmom Italy |Coree Srl
Piazza S. Babila 5, 20122 Milan, Italy

 

+39 02 36636 376
info@ofmom.it

For further information on the proper intake of the products, it is advisable to always contact your doctor or pharmacist.
The information on this site cannot in any way replace the direct relationship between health professional and patient. It is therefore necessary to always consult your doctor and / or pharmacist.